Table 1.
Contributing factors to obesity in 202 adults with 22q11.2DS
| Distribution of features by level of obesitya | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not obese | Obesity class | ||||||||||||
| n=202 | n=112 | I n=44 |
II n=33 |
III n=13 |
Logistic regression analysis | ||||||||
| Contributing factors | n | n | % | n | % | n | % | n | % | OR | 95% CI | P | |
| Male sex | 94 | 54 | 48.2 | 20 | 45.5 | 15 | 45.5 | 5 | 38.5 | 1.06 | 0.60 | 1.88 | 0.836 |
| Intellectual disabilityb | 117 | 71 | 63.4 | 19 | 43.2 | 21 | 63.6 | 6 | 46.2 | 0.83 | 0.46 | 1.48 | 0.524 |
| Hypothyroidism | 39 | 16 | 14.3 | 9 | 20.5 | 9 | 27.3 | 5 | 38.5 | 1.88 | 0.94 | 3.77 | 0.076 |
| CHDb | 114 | 64 | 57.1 | 21 | 47.7 | 19 | 57.6 | 10 | 76.9 | 1.82 | 0.99 | 3.34 | 0.053 |
| Psychotropic medicationsc | 119 | 54 | 48.2 | 29 | 65.9 | 27 | 81.8 | 9 | 69.2 | 3.88 | 1.93 | 7.82 | <0.001 |
| Smoking | 42 | 30 | 26.8 | 6 | 13.6 | 4 | 12.1 | 2 | 15.4 | 1.08 | 0.32 | 3.62 | 0.901 |
| Psychotropic medications x Smoking | 28 | 21 | 18.8 | 3 | 6.8 | 3 | 9.1 | 1 | 7.7 | 0.13 | 0.03 | 0.60 | 0.009 |
| Med | IQR | Med | IQR | Med | IQR | Med | IQR | ||||||
| Age at assessment (y) | 23.1 | 9.8 | 31.4 | 12.5 | 32.3 | 14.2 | 31.0 | 11.7 | 1.06 | 1.03 | 1.10 | <0.0001 | |
a
Not obese (BMI<30), class I (35>BMI≥30), class II (40>BMI≥35), and class III (BMI≥40) obesity
b
For details, see text
c
Lifetime use of antipsychotics, selective serotonin reuptake inhibitors, valproic acid, venlafaxine, or lithium. Of 119 subjects with a history of psychotropic medication use, 87 (73.1%) had a history of antipsychotic, with (n=70) or without (n=17), other medication use. 32 (26.9%) subjects had a history of one or more of the other psychotropic medications listed. Overall, 82 had a history of SSRI, 35 valproic acid, 12 venlafaxine and 9 lithium use.
Med: median, IQR: interquartile range, OR: odds ratio, CI: confidence interval, P: p-value, y: years.